[HTML][HTML] Antibody–drug conjugates—a tutorial review
Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …
From anthramycin to pyrrolobenzodiazepine (PBD)‐containing antibody–drug conjugates (ADCs)
Abstract The pyrrolo [2, 1‐c][1, 4] benzodiazepines (PBDs) are a family of sequence‐
selective DNA minor‐groove binding agents that form a covalent aminal bond between their …
selective DNA minor‐groove binding agents that form a covalent aminal bond between their …
Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy
Cytotoxic small‐molecule drugs have a major influence on the fate of antibody–drug
conjugates (ADCs). An ideal cytotoxic agent should be highly potent, remain stable while …
conjugates (ADCs). An ideal cytotoxic agent should be highly potent, remain stable while …
Advances in antibody–drug conjugates: a new era of targeted cancer therapy
Highlights•ADC represents a new class of targeted anticancer therapeutics.•Elucidates
selection criteria for tumor specific antigen and ADC development.•Smart linkers and fixed …
selection criteria for tumor specific antigen and ADC development.•Smart linkers and fixed …
Recent advances in synthesis and medicinal chemistry of benzodiazepines
Benzodiazepines (BZDs) represent a diverse class of bicyclic heterocyclic molecules. In the
last few years, benzodiazepines have emerged as potential therapeutic agents. As a result …
last few years, benzodiazepines have emerged as potential therapeutic agents. As a result …
Antibody-drug conjugates-stability and formulation
C Duerr, W Friess - European Journal of Pharmaceutics and …, 2019 - Elsevier
The number of antibody-drug conjugates (ADCs) on the market is expected to multiply in the
upcoming years. The main reason: this novel drug delivery system combines the benefits of …
upcoming years. The main reason: this novel drug delivery system combines the benefits of …
[HTML][HTML] Third-generation antibody drug conjugates for cancer therapy–a balancing act
M Vankemmelbeke, L Durrant - Therapeutic delivery, 2016 - Taylor & Francis
The use of monoclonal antibodies (mAbs) to target toxic payloads to cancer cells has a long
and convoluted history. Early experiments with first-generation antibody–drug conjugates …
and convoluted history. Early experiments with first-generation antibody–drug conjugates …
Design, Synthesis, and Bioevaluation of a Novel Hybrid Molecular Pyrrolobenzodiazepine–Anthracenecarboxyimide as a Payload for Antibody–Drug Conjugate
W Lai, S Zhao, Q Lai, W Zhou, M Wu… - Journal of Medicinal …, 2022 - ACS Publications
A novel series of hybrid molecules combining pyrrolobenzodiazepine (PBD) and
anthracenecarboxyimide pharmacophores were designed, synthesized, and tested for in …
anthracenecarboxyimide pharmacophores were designed, synthesized, and tested for in …
An extended pyrrolobenzodiazepine–polyamide conjugate with selectivity for a DNA sequence containing the ICB2 transcription factor binding site
F Brucoli, RM Hawkins, CH James… - Journal of medicinal …, 2013 - ACS Publications
The binding of nuclear factor Y (NF-Y) to inverted CCAAT boxes (ICBs) within the promoter
region of DNA topoisomerase IIα results in control of cell differentiation and cell cycle …
region of DNA topoisomerase IIα results in control of cell differentiation and cell cycle …